

NEXT GENERATION TREATMENTS



The next generation of hepatitis C treatments is coming. This webpage summarizes these possible hep C treatments, treatments that are currently within [the early stages of clinical trials](#). These treatments may or may not be successfully approved for use and, if they are approved, may take a number of years to do so.

If you are looking for information about hep C treatments further along in the drug approval process, please check out our [Hep C Drug Pipeline Treatments](#) page. But, if you are looking for information about currently approved hep C treatments, look for their pages in the drop-down menu under *BC's PharmaCare Covered Treatments* or check out our [Treatment Coverage Across Canada](#) page.

Treatments in the Early Stages of Clinical Trials

Pharmaceutical Companies	Treatments	Currently Targeted Genotypes
Janssen	AL-335 + Odalasvir (ACH-3102) + Simeprevir	1-6
Merck	Grazoprevir + Ruzasvir + Uprifosbuvir	1-6
	MK-2682B*	1-6

**MK-2682B is an experimental treatment regimen made up of MK-3682, grazoprevir, and ruzasvir.*

Maker: Janssen

Treatment: [AL-335 + Odalasvir \(ACH-3102\) + Simeprevir](#)

Targeted Genotype: 1-6

Treatment Description: AL-335 is a nucleotide polymerase inhibitor and odalasvir (ACH-3102) is a NS5A inhibitor. **Simeprevir (brand name Galexos)** is a NS3/4A protease inhibitors. These inhibitors work by blocking viral enzymes (protease) that enables the hep C virus to survive and replicate in host cells.

- AL-335 +
- Odalasvir (ACH-3102) +
- Simeprevir (brand name Galexos)

Possible Daily Dose: 1 pill

Step in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

- [Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV](#)
- [Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver \(EASL\)](#)

Maker: Merck

Treatment: MK-3682B

Possible Targeted Genotypes: 1-6

Potential Combinations:

- MK-3682 +
- Grazoprevir (MK-5172) +
- Ruzasvir +/-
- Ribavirin

Possible Length of Treatment: 8 – 24 weeks

Possible Daily Dose: 2 pills once daily

Step in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

- Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
- Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 with Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype 3, GT4, GT5, and GT6 Infection

Treatment: Grazoprevir + Ruzasvir + Uprifosbuvir

Possible Targeted Genotypes: 1-6

Potential Combinations:

- Grazoprevir (MK-5172) +
- Ruzasvir +
- Uprifosbuvir +/-
- Ribavirin

Possible Length of Treatment: 8 – 16 weeks

Possible Daily Dose: 1 pill once daily

Step in Drug Approval Pipeline: Step 1 – Testing

Additional Information:

- Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
- Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
- Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

The information on this website is meant as a resource only and is not intended to replace qualified medical attention. Please seek advise and guidance from your health practitioners when considering your hep C treatment options.